Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Lynparza approved in Japan for early breast cancer
Preheader (123)Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
Typography
Arial
Colors
Text Analysis
Body Words199
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px716 px
X-Spam Score-4.0
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEarly Morning

Lynparza approved in Japan for early breast cancer

Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza approved in Japan for early breast cancer